(firstQuint)Safety Study of MG1102 in Patients With Solid Tumors.

 This is an open-label, Dose Escalation Study, multicenter phase I study to evaluate the safety and tolerability, determine the pharmacokinetics, and obtain preliminary information regarding pharmacodynamics and efficacy of MG1102 in subjects with solid tumor.

 Each subject will receive on dose of MG1102 followed by a 6-day rest period.

 If the initial dose is tolerated, subject will continue with the 21 days of MG1102 administration (5 days on treatment, 2 days off treatment for 3 weeks.

) Subjects that have a tumor response as stable disease, may continue therapy on a compassionate use.

 Study Duration : for a minimum of 8 weeks.

 Safety Study of MG1102 in Patients With Solid Tumors@highlight

To investigate the safety and tolerability of a 28 day course of intravenous (IV) MG1102 in patients with solid tumors for which no standard therapy is available.

